U.S. Economic Growth Exceeds Expectations, Stock Futures Edge Lower
Stock futures edged lower after delayed economic data arrived far stronger than expected. The U.S. economy posted robust growth over the summer, the Commerce Department said, offering one of the final looks at the country's economic performance for 2025. Gross domestic product expanded at an annualized 4.3% pace in the third quarter, well above expectations. Economists had forecast growth would ease to 3.2%, down from a 3.8% annualized rate in the second quarter.In commodities, precious metals stayed firm, supported by lower volatility in rates and lingering geopolitical and macro uncertainty, while energy prices were mixed as traders weighed demand expectations heading into year-end.In pre-market trading, S&P 500 futures are down 0.18%, Nasdaq futures fell 0.23% and Dow futures are down 0.18%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Sable Offshoreup 19% after the Pipeline Hazardous Materials Safety Administration granted approval of the Las Flores Pipeline restartNovo Nordiskup 8% after Reutersthe company's newly approved version of Wegovy in pill form is planned to go straight to U.S. self-pay channels in early JanuaryHIIup 2% after The Wall Street JournalPresident Trump announcing that the U.S. Navy intends to build a new "Trump-class" battleship as part of the "Golden Fleet" initiativeZIM Integratedup 8% after update on strategic review processZai Labup 2% after announcing that China's National Medical Products Administration approved the new drug application for Cobenfy for the treatment of schizophrenia in adultsLOWER -Johnson & Johnsondown 1% after Reutersa Baltimore jury has ordered the company and its subsidiaries to pay more than $1.5B to a woman who said exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma
Get Free Real-Time Notifications for Any Stock
Analyst Views on NVO
About NVO
About the author
FDA Approves Novo Nordisk's New Weight Management Pill
- Clinical Trial Results: In the global OASIS 4 clinical trial, patients achieved an average weight loss of 16.6%, demonstrating the drug's significant efficacy in weight management, which is expected to attract more patients seeking treatment and enhance Novo Nordisk's market share.
- Cardiovascular Risk Reduction: The drug is also approved to lower cardiovascular event risks in heart disease patients, with data showing approximately a 20% reduction in risk, which not only enhances the therapeutic value but also opens new market opportunities for Novo Nordisk in heart health.
- Market Launch Plans: Novo Nordisk plans to launch the drug in the U.S. in January 2026, marking it as the first oral GLP-1 treatment, which is expected to change patient acceptance of weight loss medications and further solidify the company's leadership in the obesity treatment market.
- Global Obesity Challenge: With rising global obesity rates, particularly in Indonesia at 23.4%, Novo Nordisk's innovative drug provides a new solution to this public health crisis, highlighting the company's responsibility and mission in global health management.
Novo Nordisk Stock Rebounds, Optimistic Outlook Ahead
- Stock Recovery: Novo Nordisk's stock has surged 25% year-to-date in 2026, indicating a strong rebound from a 42% decline in 2025, reflecting renewed market confidence in its growth prospects.
- Prescription Surge: Prescriptions for the oral version of Wegovy skyrocketed to 20,392 last week, more than quadrupling the previous week's rate and significantly exceeding Bank of America's target of 2,000 prescriptions per week, showcasing robust consumer demand for the new formulation.
- Market Expansion Potential: Currently available only in the U.S., the Wegovy pill could see stock price boosts if other countries, such as the UK, approve it, thereby expanding Novo Nordisk's market share and sales channels.
- Sustained Competitive Edge: Despite the popularity of the oral version, prescriptions for the injectable form remain steady, indicating no significant market cannibalization, which may enhance the company's competitive position through a diversified product line.
